Retatrutide vs Zepbound: Which Eli Lilly Drug Produces More Weight Loss?

Overview

Eli Lilly makes both retatrutide and Zepbound (tirzepatide), and the two make up the company’s two-pronged bet on next-generation obesity drugs. Zepbound (tirzepatide 5, 10 or 15 mg) is an FDA-approved dual GIP/GLP-1 receptor agonist for chronic weight management. Retatrutide (LY3437943) is an investigational triple agonist that adds glucagon receptor activation to the same GIP/GLP-1 base. It is in Phase 3 development.

Phase 3 TRIUMPH-4 data, released in December 2025, showed -28.7% weight loss with retatrutide, which makes the comparison between the two Lilly molecules more interesting still. The real question is what glucagon receptor activation adds to a dual agonist that already works very well.

Important note: No head-to-head trial of retatrutide against tirzepatide has reported results. TRIUMPH-5, which compares the two directly, is still running (primary completion expected November 2026). The cross-trial comparisons here are for context and have major methodological limits.

Why This Comparison Matters

This comparison is unusually informative:

• The drugs share two of three receptor targets (GIP and GLP-1), which makes them a natural experiment in what glucagon receptor activation adds
• The same company makes both, which raises real questions about how Eli Lilly will position them against each other
• With TRIUMPH-4 Phase 3 data showing -28.7% weight loss, the comparison has moved from Phase 2 guesswork to Phase 3-level evidence
• Millions of people on Zepbound will want to know whether the next drug offers meaningful extra benefit

Mechanism of Action

Zepbound (Tirzepatide)

Tirzepatide is a 39-amino-acid peptide built on a GIP backbone and engineered to act on the GLP-1 receptor too. It activates two incretin receptors:

• GIP receptor activation remodels fat tissue, boosts insulin release from beta cells and may help control appetite through hypothalamic pathways
• GLP-1 receptor activation suppresses appetite, slows gastric emptying, boosts glucose-dependent insulin secretion and lowers glucagon

Tirzepatide is about 5-fold more potent at the GIP receptor than natural GIP, while keeping clinically significant GLP-1 receptor activity. This dual action produces more weight loss and better blood sugar control than selective GLP-1 receptor agonists alone.

Retatrutide

Retatrutide shares tirzepatide’s GIP and GLP-1 activity but adds a third target: the glucagon receptor (GCGR). That brings distinct metabolic effects:

• More energy use in the liver, through glucagon-driven heat production and fat burning in the mitochondria
• More fat released from fat tissue and faster clearance of fat from the liver
• Amino acid breakdown and urea production, which add to overall energy use

The glucagon component is the key difference. Both molecules cut calorie intake, but retatrutide also raises energy use. That double deficit explains its greater weight loss in clinical data.

TRIUMPH-4 Phase 3 Results: A New Benchmark

TRIUMPH-4, released in December 2025, turned the retatrutide-versus-Zepbound comparison from cross-trial Phase 2/Phase 3 guesswork into a Phase 3-versus-Phase 3 discussion. TRIUMPH-4 enrolled 445 adults with obesity and knee osteoarthritis and showed:

The -28.7% weight loss at 12 mg is the largest weight reduction ever reported for any drug in a Phase 3 clinical trial, well above Zepbound’s -22.5% in SURMOUNT-1. Even retatrutide’s lower 9 mg dose (-26.4%) beat Zepbound’s highest dose.

Efficacy Comparison

Weight Loss: Phase 3 Data

The ~6 percentage point gap at the highest thresholds (≥20% weight loss) is clinically meaningful and likely reflects the extra energy use from glucagon receptor activation. At lower thresholds (≥5%), nearly everyone responds to both drugs, which confirms that the shared GIP/GLP-1 action does most of the work.

Liver Fat Reduction

This is where glucagon receptor activation may give retatrutide its clearest advantage. In Phase 2, retatrutide cut liver fat by about 82% in relative terms, clearly more than tirzepatide in MASLD-focused studies. Glucagon receptor activation directly stimulates fat burning in the liver, which explains why liver fat clearance goes beyond what weight loss alone achieves.

Glycemic Effects

Both drugs improve blood sugar substantially. Tirzepatide cut HbA1c by about 2.0 to 2.4% in Phase 3 diabetes trials (SURPASS program). Retatrutide cut HbA1c by about 2.02% in its Phase 2 diabetes group. The effects look broadly similar, with both the dual and triple approaches giving strong glucose control.

Safety Comparison

Gastrointestinal Tolerability

In these figures, retatrutide’s GI rates are higher than Zepbound’s (nausea 43.2% vs 28%, diarrhea 33.1% vs 23%, constipation 25.0% vs 11%). The glucagon component or the drug’s greater overall potency may play a part. In the later TRIUMPH-1 trial, 11.3% stopped 12 mg because of side effects. These are cross-trial comparisons; the head-to-head TRIUMPH-5 trial has not reported.

TRIUMPH-4 Safety: Dysesthesia Signal

TRIUMPH-4 revealed a new safety finding for retatrutide: dysesthesia (abnormal sensations such as numbness, tingling or burning) in 20.9% of participants at 12 mg versus 0.7% on placebo. In the smaller Phase 2 obesity trial, skin-sensation events (hyperesthesia and related terms) were reported in 7% of retatrutide participants and 1% on placebo. The cause is under investigation, and ongoing Phase 3 trials will show more about how common and severe it is, and how much it matters clinically.

Zepbound has no similar dysesthesia signal in its clinical trial data.

Glucagon-Specific Considerations

Retatrutide’s glucagon component raises theoretical questions that do not apply to tirzepatide:

• It stimulates glucose release from the liver, which could work against blood sugar control in diabetes. Phase 2 data suggest the insulin released through GLP-1 and GIP at the same time offsets this well.
• Possible effects on amino acid metabolism and lean mass, which need further study.
• Heart rate: the Zepbound label reports a mean increase of 1 to 3 beats per minute, with no increase on placebo. In retatrutide’s Phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and then declined; the authors described the rise as similar to that seen with GLP-1 receptor agonists but the main paper does not give its size.

Cardiovascular Data

Neither drug has completed a dedicated cardiovascular outcomes trial in obesity. Tirzepatide’s SURPASS-CVOT trial in type 2 diabetes reported in July 2025 (non-inferior to dulaglutide for major adverse cardiovascular events, HR 0.92), while retatrutide has no cardiovascular outcomes data; TRIUMPH-Outcomes is running. Both improved cardiovascular risk factors (blood pressure, lipids) in their trials.

Eli Lilly Portfolio Strategy

With both molecules coming from Eli Lilly, the obvious question is how they will be positioned. They are likely to complement each other rather than compete:

• Zepbound is the established, approved product that earns revenue and builds Lilly’s position in obesity. It is the most effective approved obesity drug.
• Retatrutide is the next-generation candidate that could extend Lilly’s lead if Phase 3 confirms its Phase 2 and early Phase 3 efficacy. It may be aimed at patients who need more weight loss or have specific conditions (such as MASLD) where glucagon receptor activation adds benefit.

This lets Eli Lilly serve different groups of patients and stay ahead as obesity treatment develops.

Current Status and Availability

Zepbound

Zepbound is FDA-approved (November 2023) and on the market for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition. Doctors prescribe it and pharmacies stock it, though supply problems have affected availability at times.

Retatrutide

Retatrutide is investigational as of October 31, 2026. The Phase 3 TRIUMPH program includes 4 pivotal obesity trials (TRIUMPH-1 through TRIUMPH-4) plus the TRIUMPH-Outcomes cardiovascular outcomes trial, the TRANSCEND program (type 2 diabetes) and the SYNERGY/MACELD programs (MASH). TRIUMPH-4 topline results were announced in December 2025 (-28.7% at 12 mg/68 weeks), TRANSCEND-T2D-1 on March 19, 2026 (HbA1c -1.7 to -2.0 pp, weight -11.1 to -16.6 kg in the topline release; the Lancet paper of June 6, 2026 reported -1.94 points and -15.3% at 12 mg), TRIUMPH-1 on May 21, 2026 (-28.3% at 12 mg/80 weeks in 2,339 adults), TRIUMPH-2 and TRIUMPH-3 on July 23, 2026, and TRANSCEND-T2D-2 (head-to-head vs semaglutide) on October 28, 2026. No application has been filed. The earliest possible FDA approval is estimated at late 2027 to early 2028, with Lilly planning to file no later than Q1 2027. On October 2, 2026 the FDA ruled that retatrutide is a drug, not a biologic, so the application must be a New Drug Application (NDA); Lilly is contesting the FDA ruling in court. Retatrutide is available only through enrollment in authorized clinical trials.

Key Differences Summary

Dosing and Administration Comparison

Both are once-weekly injections under the skin:

Both need a gradual dose increase to limit GI side effects. The weekly injection routine would feel much the same.

Who Might Benefit From Each

Zepbound Is the Right Choice For

• Patients who need treatment now: Zepbound is approved and available
• Patients with moderate obesity (BMI 30-40) who want proven efficacy
• Patients who want an established safety profile with full Phase 3 data
• Patients whose insurance covers Zepbound for weight management

Retatrutide May Be More Appropriate For (Once Approved)

• Patients with severe obesity (BMI ≥40) who need the most weight loss possible
• Patients with significant MASLD/MASH who would benefit from direct liver fat clearance through glucagon receptor activation
• Patients who have tried Zepbound but need more weight loss
• Patients with weight-related conditions (like knee osteoarthritis, as studied in TRIUMPH-4) where maximum weight loss helps the condition

The Weight Loss Gap in Context

The roughly 6 percentage point gap between Zepbound (-22.5%) and retatrutide (-28.7%) makes a real difference in everyday terms. For a patient weighing 250 pounds (113 kg):

• Zepbound: Expected loss of approximately 56 pounds (25 kg)
• Retatrutide: Expected loss of approximately 72 pounds (33 kg)
• Difference: Approximately 16 additional pounds (7 kg) of weight loss

At the high end, this extra weight loss can have an outsized effect, improving joint function, sleep apnea, cardiovascular risk factors and metabolic health beyond what smaller losses achieve.

Clinical Implications

Zepbound is currently the most effective FDA-approved obesity drug, with Phase 3 data showing more than 20% weight loss in most patients at the highest dose. It has an established safety profile, is on the market and has a growing evidence base across several indications.

Retatrutide’s TRIUMPH-4 Phase 3 data confirmed it can produce even more weight loss (-28.7% at 12 mg), backing up the Phase 2 signal and setting a new benchmark for drug-based weight loss. The glucagon component explains how. But the dysesthesia signal found in TRIUMPH-4 needs careful study in ongoing trials.

How the two drugs fit together in Eli Lilly’s lineup will depend on retatrutide’s full Phase 3 data, regulatory decisions, how much the dysesthesia finding matters, pricing, and the situations where glucagon receptor activation adds real benefit on top of what dual GIP/GLP-1 action already delivers.

Frequently Asked Questions

How much more weight loss does retatrutide produce compared to Zepbound?

In Phase 3 data, retatrutide 12 mg produced -28.7% weight loss at 68 weeks (TRIUMPH-4), compared with Zepbound’s -22.5% at 72 weeks (SURMOUNT-1), a difference of about 6 percentage points. These are cross-trial comparisons with different patient populations, and no head-to-head trial has reported.

Will retatrutide replace Zepbound?

Unlikely. Eli Lilly presents the two as complementary products. Zepbound is the established, approved treatment for most people with obesity, while retatrutide may be aimed at people who need the most weight loss possible or have conditions like fatty liver disease. Both are expected to stay in Lilly’s lineup.

When can I switch from Zepbound to retatrutide?

As of October 31, 2026, retatrutide is not approved and is only available in clinical trials. If you take Zepbound, do not stop it in anticipation of retatrutide. The earliest possible commercial availability is late 2027 to early 2028 (filing planned no later than Q1 2027), assuming FDA approval.

What is the dysesthesia side effect found in TRIUMPH-4?

Dysesthesia means abnormal sensations such as numbness, tingling or burning. In TRIUMPH-4, it was reported in 20.9% of people on retatrutide 12 mg versus 0.7% on placebo. This was a new finding not seen in Phase 2 trials. The cause is being investigated, and ongoing Phase 3 trials will show how much it matters clinically.

Are retatrutide and Zepbound both weekly injections?

Yes. Both are once-weekly injections under the skin from pre-filled pens. The routine, including rotating injection sites and storage, would be similar for both.

Does retatrutide work better for liver fat than Zepbound?

Yes, on the data available. Retatrutide cut liver fat by about 82% in relative terms in Phase 2, much more than the moderate reductions seen with tirzepatide. That is because retatrutide’s glucagon component directly stimulates fat burning in the liver, which Zepbound does not do. For people with significant fatty liver disease (MASLD/MASH), this may be a key difference.

What happens to Zepbound patients when retatrutide is approved?

You would not need to switch. Zepbound will stay available and effective for most patients. Retatrutide would be an extra option for people who need more weight loss, have significant liver disease or have not done well enough on Zepbound. Any decision to switch would be made with your doctor, based on your needs and goals.

Is retatrutide’s -28.7% weight loss really that much better than Zepbound’s -22.5%?

The 6 percentage point gap is clinically meaningful. For a 250-pound patient, it means about 16 extra pounds of weight loss. Across the population, more people reach the ≥20% and ≥25% weight loss thresholds on retatrutide, and these are increasingly seen as clinically important targets. Still, both drugs produce far more weight loss than any earlier medicine, and Zepbound remains a highly effective treatment.